Related Experiment Video
Updated: Dec 9, 2025

A Data-Driven Approach to Quantifying Immune States in Sepsis
Published on: February 7, 2025
The promise and pitfalls of composite endpoints in sepsis and COVID-19 clinical trials
P M Brown1,2, Tormod Rogne1,3, Erik Solligård1,3
1Gemini Center for Sepsis Research, Clinic of Anesthesia and Intensive Care, St. Olav's hospital, Trondheim University Hospital, Trondheim, Norway.
Abstract:
Composite endpoints reveal the tendency for statistical convention to arise locally within subfields. Composites are familiar in cardiovascular trials, yet almost unknown in sepsis. However, the VITAMINS trial in patients with septic shock adopted a composite of mortality and vasopressor-free days, and an ordinal scale describing patient status rapidly became standard in COVID studies. Aware that recent use could incite interest in such endpoints, we are motivated to flag their potential value and pitfalls for sepsis research and COVID studies.
Related Concept Videos
Clinical Trials: Overview
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Clinical Trials
There are four phases in a clinical trial. A phase one...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Pneumonia III: Complications and Assessment
Bioavailability Study Design: Healthy Subjects Versus Patients

